Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migration and homing to secondary lymphoid tissue: association with prolonged allograft survival.
The novel immunomodulator FTY720 is a prototypic sphingosine-1-phosphate (S1P) receptor agonist that regulates lymphocyte migration and prolongs allograft survival. Skin dendritic cells (DC) play important roles in cutaneous immunity. We investigated the migration and function of skin DC exposed to FTY720 in vivo, or to its metabolite FTY720 phosphate (P) in vitro. C57BL/10 (H2(b)) recipient (but not donor) FTY720 treatment prolonged median skin C3H (H2(k)) allograft survival significantly, from 12 to 34.5 days. Non-transplanted, FTY720-treated mice revealed a marked increase in skin DC, although total DC in skin-draining lymph nodes (DLN) were unchanged compared with controls. Fewer allogeneic donor DC migrated to DLN of FTY720-treated graft recipients. DC that migrated from the skin of FTY720-treated mice showed reduced MHC class II, CD86 and CCR7 expression, suggesting impaired migratory potential to secondary lymphoid tissue, that correlated with DC retention in skin, and reduced T cell stimulatory activity. Fewer DC migrated from normal skin explants exposed to the FTY720 metabolite, FTY720P than to control medium. DC that did migrate expressed lower levels of MHC class II, CD86 and CCR7, and inferior T cell stimulatory ability. These data demonstrate S1P signaling regulates skin DC trafficking and modulates MHC class II, costimulatory, and homing receptor molecule expression that impairs their ability to elicit allogeneic T cell responses.
Lan
Yuk Yuen
YY
Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Tokita
Daisuke
D
Wang
Zhiliang
Z
Wang
Hao Chen
HC
Zhan
Jianghua
J
Brinkmann
Volker
V
Thomson
Angus W
AW
D000818:Animals; D051940:B7-2 Antigen / Q000378:metabolism; D002465:Cell Movement / Q000187:drug effects* / Q000276:immunology; D000068876:Fingolimod Hydrochloride; D006084:Graft Rejection / Q000276:immunology; D006085:Graft Survival / Q000187:drug effects* / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000378:metabolism; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007801:Langerhans Cells / Q000187:drug effects* / Q000276:immunology; D008198:Lymph Nodes / Q000276:immunology; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D010755:Organophosphates / Q000494:pharmacology; D011409:Propylene Glycols / Q000494:pharmacology*; D054400:Receptors, CCR7 / Q000378:metabolism; D049349:Receptors, Lysosphingolipid / Q000819:agonists* / Q000276:immunology; D016038:Skin Transplantation / Q000276:immunology*; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D014184:Transplantation, Homologous / Q000276:immunology
D051940:B7-2 Antigen; C515371:Ccr7 protein, mouse; C497965:Cd86 protein, mouse; C525008:FTY 720P; D000949:Histocompatibility Antigens Class II; D007166:Immunosuppressive Agents; D010755:Organophosphates; D011409:Propylene Glycols; D054400:Receptors, CCR7; D049349:Receptors, Lysosphingolipid; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine